| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 138 | 2022 | 1548 | 11.070 |
Why?
|
| Insulin Resistance | 91 | 2020 | 494 | 7.660 |
Why?
|
| Atherosclerosis | 61 | 2021 | 718 | 5.900 |
Why?
|
| African Americans | 79 | 2019 | 1522 | 4.180 |
Why?
|
| Obesity | 45 | 2022 | 1081 | 3.550 |
Why?
|
| Hispanic Americans | 59 | 2019 | 947 | 3.520 |
Why?
|
| Insulin | 37 | 2020 | 363 | 3.150 |
Why?
|
| Middle Aged | 213 | 2021 | 11167 | 3.130 |
Why?
|
| Male | 243 | 2022 | 18050 | 2.950 |
Why?
|
| Female | 243 | 2022 | 18308 | 2.950 |
Why?
|
| Blood Glucose | 46 | 2021 | 483 | 2.890 |
Why?
|
| Humans | 269 | 2022 | 29168 | 2.490 |
Why?
|
| Polymorphism, Single Nucleotide | 54 | 2020 | 1241 | 2.440 |
Why?
|
| Genome-Wide Association Study | 38 | 2021 | 618 | 2.380 |
Why?
|
| Cardiovascular Diseases | 39 | 2020 | 1046 | 2.360 |
Why?
|
| Aged | 139 | 2022 | 9602 | 2.290 |
Why?
|
| Diabetes Mellitus | 16 | 2022 | 356 | 2.260 |
Why?
|
| Cohort Studies | 55 | 2022 | 1709 | 2.230 |
Why?
|
| European Continental Ancestry Group | 54 | 2019 | 1210 | 2.160 |
Why?
|
| F2-Isoprostanes | 7 | 2017 | 22 | 2.150 |
Why?
|
| Risk Factors | 90 | 2021 | 3550 | 2.070 |
Why?
|
| Life Style | 23 | 2021 | 370 | 2.040 |
Why?
|
| Carotid Artery Diseases | 11 | 2016 | 121 | 2.030 |
Why?
|
| Genetic Predisposition to Disease | 35 | 2020 | 950 | 1.970 |
Why?
|
| Adipose Tissue | 15 | 2018 | 334 | 1.850 |
Why?
|
| Adiposity | 20 | 2017 | 208 | 1.820 |
Why?
|
| Adult | 108 | 2020 | 8580 | 1.810 |
Why?
|
| Weight Loss | 23 | 2021 | 411 | 1.750 |
Why?
|
| Body Mass Index | 41 | 2020 | 887 | 1.640 |
Why?
|
| Fatty Acids | 7 | 2020 | 94 | 1.640 |
Why?
|
| Calcinosis | 11 | 2016 | 159 | 1.580 |
Why?
|
| Membrane Proteins | 9 | 2019 | 269 | 1.440 |
Why?
|
| Coronary Artery Disease | 13 | 2011 | 378 | 1.410 |
Why?
|
| Albuminuria | 17 | 2017 | 209 | 1.410 |
Why?
|
| Mexican Americans | 5 | 2019 | 64 | 1.380 |
Why?
|
| Intra-Abdominal Fat | 8 | 2013 | 68 | 1.350 |
Why?
|
| United States | 53 | 2021 | 3633 | 1.340 |
Why?
|
| Lipase | 5 | 2019 | 29 | 1.290 |
Why?
|
| Genetic Variation | 10 | 2019 | 284 | 1.250 |
Why?
|
| Bone Density | 10 | 2018 | 191 | 1.230 |
Why?
|
| Fasting | 17 | 2016 | 94 | 1.220 |
Why?
|
| African Continental Ancestry Group | 25 | 2019 | 378 | 1.220 |
Why?
|
| Arteriosclerosis | 18 | 2005 | 127 | 1.200 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2020 | 184 | 1.120 |
Why?
|
| Fatty Liver | 6 | 2013 | 72 | 1.080 |
Why?
|
| Weight Gain | 7 | 2016 | 106 | 1.060 |
Why?
|
| Prospective Studies | 31 | 2022 | 1981 | 1.050 |
Why?
|
| Overweight | 14 | 2021 | 256 | 1.040 |
Why?
|
| Incidence | 31 | 2021 | 1097 | 1.030 |
Why?
|
| Risk Assessment | 19 | 2021 | 1308 | 1.010 |
Why?
|
| Genetic Loci | 11 | 2019 | 164 | 1.010 |
Why?
|
| Lipids | 10 | 2019 | 219 | 1.000 |
Why?
|
| Genome, Human | 10 | 2021 | 149 | 0.970 |
Why?
|
| Follow-Up Studies | 36 | 2020 | 2130 | 0.970 |
Why?
|
| Homeostasis | 10 | 2019 | 146 | 0.950 |
Why?
|
| Diet | 9 | 2017 | 350 | 0.940 |
Why?
|
| Vitamin D | 10 | 2018 | 174 | 0.930 |
Why?
|
| Lipogenesis | 2 | 2020 | 19 | 0.920 |
Why?
|
| Hypertension | 15 | 2017 | 980 | 0.910 |
Why?
|
| Residence Characteristics | 3 | 2021 | 160 | 0.910 |
Why?
|
| Adiponectin | 11 | 2017 | 117 | 0.900 |
Why?
|
| Cross-Sectional Studies | 35 | 2021 | 1310 | 0.900 |
Why?
|
| Glucose Tolerance Test | 24 | 2017 | 134 | 0.890 |
Why?
|
| Genotype | 29 | 2020 | 826 | 0.890 |
Why?
|
| Occupations | 2 | 2012 | 10 | 0.890 |
Why?
|
| Alanine Transaminase | 5 | 2019 | 45 | 0.880 |
Why?
|
| Aortic Diseases | 2 | 2016 | 57 | 0.880 |
Why?
|
| Glucose Intolerance | 14 | 2013 | 44 | 0.870 |
Why?
|
| Aged, 80 and over | 32 | 2021 | 3731 | 0.860 |
Why?
|
| Prediabetic State | 8 | 2016 | 54 | 0.850 |
Why?
|
| Diabetes Complications | 8 | 2018 | 184 | 0.850 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 49 | 0.850 |
Why?
|
| Occupational Diseases | 2 | 2012 | 84 | 0.830 |
Why?
|
| Prevalence | 16 | 2022 | 887 | 0.820 |
Why?
|
| Aspartate Aminotransferases | 4 | 2019 | 28 | 0.810 |
Why?
|
| Smoking | 8 | 2019 | 433 | 0.800 |
Why?
|
| Triglycerides | 14 | 2020 | 222 | 0.780 |
Why?
|
| Young Adult | 21 | 2020 | 2400 | 0.780 |
Why?
|
| Aging | 7 | 2017 | 874 | 0.770 |
Why?
|
| Cholesterol, HDL | 11 | 2019 | 173 | 0.770 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2017 | 890 | 0.770 |
Why?
|
| Blood Pressure | 18 | 2017 | 874 | 0.760 |
Why?
|
| Risk Reduction Behavior | 10 | 2018 | 111 | 0.720 |
Why?
|
| Phenotype | 18 | 2020 | 676 | 0.710 |
Why?
|
| Abdominal Fat | 5 | 2017 | 46 | 0.710 |
Why?
|
| Coronary Vessels | 7 | 2017 | 160 | 0.700 |
Why?
|
| Insulin-Secreting Cells | 9 | 2018 | 58 | 0.700 |
Why?
|
| Disease Progression | 9 | 2016 | 594 | 0.680 |
Why?
|
| Subcutaneous Fat | 4 | 2016 | 45 | 0.680 |
Why?
|
| Abdomen | 4 | 2008 | 43 | 0.670 |
Why?
|
| Nutrigenomics | 1 | 2017 | 2 | 0.670 |
Why?
|
| Environment | 1 | 2017 | 49 | 0.650 |
Why?
|
| Carotid Arteries | 7 | 2015 | 104 | 0.640 |
Why?
|
| Metabolome | 4 | 2018 | 33 | 0.630 |
Why?
|
| Alleles | 11 | 2021 | 276 | 0.630 |
Why?
|
| Cognition Disorders | 4 | 2014 | 396 | 0.620 |
Why?
|
| Heart Failure | 7 | 2018 | 575 | 0.610 |
Why?
|
| Population Surveillance | 6 | 2021 | 116 | 0.600 |
Why?
|
| Metabolic Clearance Rate | 3 | 2014 | 18 | 0.570 |
Why?
|
| Diabetic Angiopathies | 11 | 2016 | 150 | 0.560 |
Why?
|
| Physical Fitness | 4 | 2014 | 116 | 0.560 |
Why?
|
| Adolescent | 20 | 2020 | 3242 | 0.560 |
Why?
|
| Longitudinal Studies | 13 | 2019 | 705 | 0.560 |
Why?
|
| Tunica Intima | 6 | 2014 | 67 | 0.550 |
Why?
|
| Continental Population Groups | 5 | 2019 | 231 | 0.550 |
Why?
|
| Time Factors | 18 | 2019 | 2007 | 0.540 |
Why?
|
| Sleep | 2 | 2019 | 85 | 0.540 |
Why?
|
| Patient Education as Topic | 6 | 2015 | 230 | 0.530 |
Why?
|
| Ethnic Groups | 16 | 2020 | 452 | 0.520 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2012 | 10 | 0.500 |
Why?
|
| Minority Groups | 2 | 2011 | 63 | 0.490 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2015 | 170 | 0.490 |
Why?
|
| Health | 1 | 2013 | 14 | 0.480 |
Why?
|
| Quantitative Trait Loci | 10 | 2021 | 153 | 0.480 |
Why?
|
| Lung | 2 | 2012 | 231 | 0.480 |
Why?
|
| Waist Circumference | 8 | 2020 | 90 | 0.470 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 5 | 2017 | 47 | 0.460 |
Why?
|
| DNA | 4 | 2009 | 214 | 0.440 |
Why?
|
| Glucose | 7 | 2018 | 175 | 0.440 |
Why?
|
| Cholesterol, LDL | 9 | 2019 | 167 | 0.440 |
Why?
|
| Predictive Value of Tests | 15 | 2020 | 788 | 0.440 |
Why?
|
| Vitamin D Deficiency | 5 | 2018 | 92 | 0.440 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 30 | 0.430 |
Why?
|
| Lung Diseases | 1 | 2012 | 46 | 0.430 |
Why?
|
| Carotid Artery, Common | 4 | 2007 | 39 | 0.410 |
Why?
|
| Oxidative Stress | 4 | 2017 | 254 | 0.390 |
Why?
|
| Pedigree | 9 | 2014 | 150 | 0.390 |
Why?
|
| Dietary Fats | 3 | 2018 | 109 | 0.390 |
Why?
|
| Brain | 4 | 2019 | 949 | 0.390 |
Why?
|
| Linear Models | 9 | 2019 | 429 | 0.390 |
Why?
|
| Quantitative Trait, Heritable | 3 | 2021 | 51 | 0.390 |
Why?
|
| Odds Ratio | 9 | 2019 | 457 | 0.380 |
Why?
|
| Coronary Disease | 4 | 2017 | 207 | 0.370 |
Why?
|
| Contrast Media | 2 | 2011 | 125 | 0.370 |
Why?
|
| Liver | 6 | 2019 | 470 | 0.370 |
Why?
|
| Motor Activity | 4 | 2015 | 305 | 0.370 |
Why?
|
| Aortic Aneurysm, Abdominal | 2 | 2021 | 47 | 0.370 |
Why?
|
| Polymorphism, Genetic | 3 | 2008 | 215 | 0.360 |
Why?
|
| Family | 8 | 2018 | 121 | 0.360 |
Why?
|
| Texas | 9 | 2014 | 41 | 0.360 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 65 | 0.360 |
Why?
|
| Gene Frequency | 8 | 2019 | 274 | 0.360 |
Why?
|
| Lipid Metabolism | 3 | 2019 | 103 | 0.360 |
Why?
|
| Aorta, Abdominal | 3 | 2007 | 29 | 0.350 |
Why?
|
| Forecasting | 4 | 2019 | 132 | 0.350 |
Why?
|
| Risk | 9 | 2018 | 295 | 0.350 |
Why?
|
| Age Factors | 7 | 2020 | 1105 | 0.350 |
Why?
|
| Dairy Products | 3 | 2018 | 12 | 0.340 |
Why?
|
| Case-Control Studies | 8 | 2019 | 912 | 0.340 |
Why?
|
| Exercise | 6 | 2019 | 563 | 0.330 |
Why?
|
| Linkage Disequilibrium | 8 | 2019 | 222 | 0.320 |
Why?
|
| Stroke | 4 | 2017 | 507 | 0.310 |
Why?
|
| Regression Analysis | 8 | 2017 | 275 | 0.310 |
Why?
|
| C-Reactive Protein | 9 | 2016 | 238 | 0.310 |
Why?
|
| Colorado | 7 | 2014 | 45 | 0.310 |
Why?
|
| Islets of Langerhans | 5 | 2016 | 73 | 0.310 |
Why?
|
| Radiography | 4 | 2013 | 359 | 0.310 |
Why?
|
| Amyloid | 2 | 2017 | 16 | 0.310 |
Why?
|
| Lymphotoxin-alpha | 1 | 2006 | 5 | 0.300 |
Why?
|
| Sex Factors | 10 | 2019 | 635 | 0.300 |
Why?
|
| Fibroblast Growth Factors | 2 | 2017 | 36 | 0.300 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2017 | 159 | 0.300 |
Why?
|
| Proteins | 3 | 2019 | 145 | 0.290 |
Why?
|
| Depression | 2 | 2022 | 351 | 0.290 |
Why?
|
| Anthropometry | 5 | 2017 | 83 | 0.290 |
Why?
|
| Hormone Replacement Therapy | 2 | 2007 | 88 | 0.280 |
Why?
|
| Diabetic Nephropathies | 5 | 2016 | 246 | 0.280 |
Why?
|
| Prognosis | 7 | 2020 | 1447 | 0.280 |
Why?
|
| Inflammation | 5 | 2017 | 510 | 0.270 |
Why?
|
| Logistic Models | 8 | 2019 | 724 | 0.270 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2004 | 26 | 0.260 |
Why?
|
| Postmenopause | 3 | 2007 | 396 | 0.260 |
Why?
|
| Heart | 3 | 2020 | 179 | 0.260 |
Why?
|
| Obesity, Abdominal | 2 | 2017 | 24 | 0.260 |
Why?
|
| Apolipoproteins | 4 | 2014 | 219 | 0.250 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2015 | 56 | 0.250 |
Why?
|
| Indians, North American | 2 | 2020 | 112 | 0.250 |
Why?
|
| Genetic Association Studies | 8 | 2015 | 171 | 0.250 |
Why?
|
| Ultrasonography | 6 | 2021 | 352 | 0.250 |
Why?
|
| Body Fat Distribution | 3 | 2019 | 37 | 0.240 |
Why?
|
| Chromosome Mapping | 6 | 2019 | 213 | 0.240 |
Why?
|
| Health Surveys | 2 | 2017 | 188 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2016 | 204 | 0.240 |
Why?
|
| Lod Score | 8 | 2017 | 86 | 0.240 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 313 | 0.230 |
Why?
|
| Medicare | 1 | 2004 | 177 | 0.230 |
Why?
|
| Sex Characteristics | 6 | 2016 | 174 | 0.230 |
Why?
|
| Multivariate Analysis | 7 | 2019 | 646 | 0.230 |
Why?
|
| Proportional Hazards Models | 7 | 2018 | 722 | 0.230 |
Why?
|
| Body Composition | 3 | 2015 | 367 | 0.220 |
Why?
|
| Life Change Events | 1 | 2022 | 21 | 0.220 |
Why?
|
| gamma-Glutamyltransferase | 2 | 2019 | 9 | 0.220 |
Why?
|
| Myocardial Infarction | 3 | 2018 | 411 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2018 | 73 | 0.220 |
Why?
|
| Loneliness | 1 | 2022 | 6 | 0.220 |
Why?
|
| Cough | 2 | 2012 | 19 | 0.220 |
Why?
|
| Fibrinogen | 5 | 2017 | 42 | 0.220 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2017 | 109 | 0.210 |
Why?
|
| Comorbidity | 4 | 2016 | 546 | 0.210 |
Why?
|
| Organ Size | 3 | 2019 | 208 | 0.210 |
Why?
|
| Pericardium | 3 | 2010 | 53 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 1223 | 0.210 |
Why?
|
| Family Health | 6 | 2011 | 86 | 0.210 |
Why?
|
| Lipoproteins | 3 | 2013 | 82 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 6 | 2017 | 309 | 0.200 |
Why?
|
| Epistasis, Genetic | 2 | 2018 | 50 | 0.200 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2019 | 19 | 0.200 |
Why?
|
| North Carolina | 8 | 2019 | 1407 | 0.200 |
Why?
|
| Child | 5 | 2020 | 2174 | 0.200 |
Why?
|
| Receptor, Melatonin, MT2 | 2 | 2018 | 5 | 0.200 |
Why?
|
| Cardiology | 1 | 2021 | 72 | 0.200 |
Why?
|
| Positron-Emission Tomography | 5 | 2020 | 178 | 0.190 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2020 | 11 | 0.190 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 42 | 0.190 |
Why?
|
| Amino Acids, Branched-Chain | 2 | 2018 | 4 | 0.190 |
Why?
|
| Diet Records | 2 | 2017 | 31 | 0.190 |
Why?
|
| Spine | 2 | 2018 | 43 | 0.190 |
Why?
|
| Phylogeny | 1 | 2019 | 59 | 0.190 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 96 | 0.190 |
Why?
|
| Apolipoprotein E4 | 2 | 2018 | 58 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 870 | 0.190 |
Why?
|
| Eicosanoic Acids | 1 | 2019 | 1 | 0.180 |
Why?
|
| Infant | 2 | 2020 | 948 | 0.180 |
Why?
|
| Electronic Health Records | 1 | 2020 | 114 | 0.180 |
Why?
|
| Kidney Diseases | 3 | 2014 | 255 | 0.180 |
Why?
|
| Proinsulin | 3 | 2011 | 9 | 0.180 |
Why?
|
| HLA-D Antigens | 1 | 2019 | 1 | 0.180 |
Why?
|
| Reproducibility of Results | 5 | 2017 | 705 | 0.180 |
Why?
|
| Diet, Reducing | 3 | 2015 | 90 | 0.180 |
Why?
|
| Heart Ventricles | 1 | 2019 | 117 | 0.170 |
Why?
|
| Body Weight | 2 | 2011 | 297 | 0.170 |
Why?
|
| Child, Preschool | 2 | 2020 | 1170 | 0.170 |
Why?
|
| Antihypertensive Agents | 2 | 2016 | 378 | 0.170 |
Why?
|
| Mass Screening | 1 | 2020 | 204 | 0.170 |
Why?
|
| Dementia | 2 | 2018 | 225 | 0.170 |
Why?
|
| Genetic Testing | 1 | 2019 | 95 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 2 | 2019 | 47 | 0.170 |
Why?
|
| Asthma | 2 | 2012 | 386 | 0.170 |
Why?
|
| Life Expectancy | 1 | 2018 | 16 | 0.170 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 202 | 0.170 |
Why?
|
| Heart Rate | 1 | 2020 | 330 | 0.170 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 231 | 0.160 |
Why?
|
| Infant, Newborn | 1 | 2020 | 581 | 0.160 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 31 | 0.160 |
Why?
|
| Vitamin D-Binding Protein | 2 | 2015 | 12 | 0.160 |
Why?
|
| Disabled Persons | 1 | 2018 | 78 | 0.160 |
Why?
|
| Waist-Hip Ratio | 3 | 2019 | 39 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2011 | 458 | 0.160 |
Why?
|
| Cardiovascular System | 1 | 2017 | 41 | 0.160 |
Why?
|
| Frail Elderly | 1 | 2017 | 59 | 0.150 |
Why?
|
| Ventricular Premature Complexes | 1 | 2017 | 12 | 0.150 |
Why?
|
| Microsatellite Repeats | 2 | 2014 | 30 | 0.150 |
Why?
|
| Atrial Premature Complexes | 1 | 2017 | 15 | 0.150 |
Why?
|
| NFI Transcription Factors | 1 | 2016 | 13 | 0.150 |
Why?
|
| Laminin | 1 | 2016 | 14 | 0.150 |
Why?
|
| Amino Acids | 1 | 2016 | 40 | 0.150 |
Why?
|
| Haplotypes | 4 | 2019 | 254 | 0.150 |
Why?
|
| Lipoproteins, HDL | 3 | 2014 | 271 | 0.150 |
Why?
|
| C-Peptide | 2 | 2017 | 26 | 0.150 |
Why?
|
| Creatinine | 6 | 2017 | 185 | 0.150 |
Why?
|
| Parathyroid Hormone | 1 | 2016 | 39 | 0.140 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 7 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2017 | 3117 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 213 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2016 | 3111 | 0.140 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2015 | 3 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2016 | 56 | 0.140 |
Why?
|
| Quality of Life | 1 | 2021 | 793 | 0.140 |
Why?
|
| Research Design | 3 | 2019 | 270 | 0.140 |
Why?
|
| Fractures, Bone | 1 | 2017 | 141 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 695 | 0.140 |
Why?
|
| Stress, Physiological | 1 | 2015 | 45 | 0.140 |
Why?
|
| Energy Metabolism | 2 | 2018 | 140 | 0.130 |
Why?
|
| Sex Distribution | 3 | 2017 | 189 | 0.130 |
Why?
|
| Genome | 1 | 2014 | 43 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2017 | 372 | 0.130 |
Why?
|
| Hippocampus | 1 | 2016 | 187 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 68 | 0.130 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2014 | 6 | 0.130 |
Why?
|
| HLA-B27 Antigen | 1 | 2014 | 8 | 0.130 |
Why?
|
| HMGA2 Protein | 1 | 2014 | 15 | 0.130 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2014 | 11 | 0.130 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 13 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2017 | 325 | 0.130 |
Why?
|
| Health Status | 1 | 2017 | 357 | 0.130 |
Why?
|
| Atrial Function, Left | 1 | 2014 | 18 | 0.130 |
Why?
|
| Intracranial Hemorrhages | 1 | 2014 | 31 | 0.130 |
Why?
|
| Glucose Clamp Technique | 1 | 2014 | 13 | 0.130 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2014 | 4 | 0.130 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2014 | 7 | 0.130 |
Why?
|
| Models, Biological | 4 | 2011 | 377 | 0.130 |
Why?
|
| Feeding Behavior | 2 | 2013 | 160 | 0.130 |
Why?
|
| Ethylene Glycols | 3 | 2019 | 8 | 0.130 |
Why?
|
| Neoplasms | 1 | 2020 | 608 | 0.120 |
Why?
|
| Heart Atria | 1 | 2014 | 65 | 0.120 |
Why?
|
| Aniline Compounds | 3 | 2019 | 25 | 0.120 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2013 | 26 | 0.120 |
Why?
|
| Eggs | 1 | 2013 | 4 | 0.120 |
Why?
|
| Energy Intake | 2 | 2012 | 122 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2014 | 330 | 0.120 |
Why?
|
| Inpatients | 1 | 2013 | 53 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2014 | 101 | 0.120 |
Why?
|
| Cholesterol, Dietary | 1 | 2013 | 37 | 0.120 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2013 | 36 | 0.120 |
Why?
|
| Body Constitution | 4 | 2005 | 27 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 271 | 0.120 |
Why?
|
| Demography | 4 | 2016 | 110 | 0.120 |
Why?
|
| Apolipoproteins B | 3 | 2013 | 44 | 0.110 |
Why?
|
| Counseling | 1 | 2012 | 79 | 0.110 |
Why?
|
| Data Collection | 2 | 2010 | 162 | 0.110 |
Why?
|
| Bronchitis, Chronic | 1 | 2012 | 2 | 0.110 |
Why?
|
| Models, Statistical | 2 | 2014 | 156 | 0.110 |
Why?
|
| Dyslipidemias | 2 | 2013 | 52 | 0.110 |
Why?
|
| Bronchitis | 1 | 2012 | 2 | 0.110 |
Why?
|
| Respiratory Sounds | 1 | 2012 | 10 | 0.110 |
Why?
|
| Lipid Peroxidation | 2 | 2017 | 36 | 0.110 |
Why?
|
| Spirometry | 1 | 2012 | 32 | 0.110 |
Why?
|
| Airway Obstruction | 1 | 2012 | 30 | 0.110 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 110 | 0.110 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 105 | 0.110 |
Why?
|
| Peptide Fragments | 2 | 2016 | 486 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 496 | 0.110 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 40 | 0.110 |
Why?
|
| Hospitalization | 2 | 2016 | 397 | 0.110 |
Why?
|
| Promoter Regions, Genetic | 2 | 2009 | 223 | 0.100 |
Why?
|
| Hypercholesterolemia | 2 | 2017 | 59 | 0.100 |
Why?
|
| Integrin beta3 | 1 | 2011 | 10 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 177 | 0.100 |
Why?
|
| Survival Analysis | 2 | 2020 | 462 | 0.100 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2011 | 31 | 0.100 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 12 | 0.100 |
Why?
|
| RGS Proteins | 1 | 2011 | 19 | 0.100 |
Why?
|
| Coffee | 1 | 2010 | 10 | 0.100 |
Why?
|
| Caloric Restriction | 2 | 2015 | 92 | 0.100 |
Why?
|
| Eating | 1 | 2011 | 74 | 0.100 |
Why?
|
| Food Preferences | 1 | 2011 | 36 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 167 | 0.100 |
Why?
|
| Caffeine | 1 | 2010 | 31 | 0.100 |
Why?
|
| Echocardiography | 3 | 2019 | 143 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2010 | 34 | 0.100 |
Why?
|
| Internationality | 1 | 2010 | 22 | 0.100 |
Why?
|
| Transcription Factors | 3 | 2019 | 194 | 0.100 |
Why?
|
| Sleep Deprivation | 1 | 2010 | 8 | 0.100 |
Why?
|
| P-Selectin | 2 | 2011 | 11 | 0.100 |
Why?
|
| Genetic Markers | 4 | 2013 | 135 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2009 | 13 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2011 | 100 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 302 | 0.090 |
Why?
|
| Statistics as Topic | 3 | 2017 | 106 | 0.090 |
Why?
|
| Southwestern United States | 1 | 2009 | 3 | 0.090 |
Why?
|
| Asian Americans | 2 | 2013 | 99 | 0.090 |
Why?
|
| Europe | 3 | 2018 | 83 | 0.090 |
Why?
|
| Tunica Media | 2 | 2014 | 33 | 0.090 |
Why?
|
| Fibrosis | 1 | 2009 | 113 | 0.090 |
Why?
|
| Minnesota | 2 | 2019 | 18 | 0.090 |
Why?
|
| Morbidity | 2 | 2020 | 89 | 0.090 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 132 | 0.090 |
Why?
|
| Fluorine Radioisotopes | 2 | 2019 | 21 | 0.090 |
Why?
|
| Spleen | 1 | 2009 | 83 | 0.090 |
Why?
|
| Exercise Test | 3 | 2017 | 190 | 0.090 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 17 | 0.080 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2008 | 7 | 0.080 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2008 | 35 | 0.080 |
Why?
|
| Calcitriol | 1 | 2008 | 24 | 0.080 |
Why?
|
| Epidemiologic Methods | 2 | 2005 | 23 | 0.080 |
Why?
|
| Behavior Therapy | 3 | 2015 | 89 | 0.080 |
Why?
|
| Brachial Artery | 1 | 2008 | 66 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2006 | 39 | 0.080 |
Why?
|
| Pain | 1 | 2010 | 276 | 0.080 |
Why?
|
| Dietary Fiber | 1 | 2007 | 19 | 0.080 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2019 | 115 | 0.080 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2018 | 9 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 356 | 0.080 |
Why?
|
| Lipoprotein Lipase | 1 | 2006 | 14 | 0.080 |
Why?
|
| Uric Acid | 1 | 2006 | 24 | 0.080 |
Why?
|
| California | 2 | 2004 | 61 | 0.080 |
Why?
|
| Kidney Function Tests | 2 | 2017 | 108 | 0.070 |
Why?
|
| Algorithms | 3 | 2020 | 468 | 0.070 |
Why?
|
| Metabolomics | 2 | 2018 | 45 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 29 | 0.070 |
Why?
|
| CD40 Ligand | 1 | 2006 | 14 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 2019 | 122 | 0.070 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2005 | 56 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2005 | 36 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 153 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2005 | 82 | 0.070 |
Why?
|
| Genome Components | 1 | 2005 | 3 | 0.070 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2005 | 80 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 13 | 0.070 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 34 | 0.070 |
Why?
|
| Health Behavior | 3 | 2014 | 213 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2005 | 101 | 0.070 |
Why?
|
| Progesterone | 1 | 2005 | 80 | 0.070 |
Why?
|
| Anticholesteremic Agents | 1 | 2005 | 37 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2005 | 97 | 0.070 |
Why?
|
| Educational Status | 2 | 2016 | 153 | 0.070 |
Why?
|
| Leptin | 2 | 2016 | 67 | 0.070 |
Why?
|
| Electrocardiography | 3 | 2018 | 564 | 0.060 |
Why?
|
| Principal Component Analysis | 2 | 2017 | 61 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2004 | 29 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 147 | 0.060 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2014 | 12 | 0.060 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2005 | 183 | 0.060 |
Why?
|
| Survival Rate | 2 | 2019 | 824 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2018 | 102 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2004 | 57 | 0.060 |
Why?
|
| Kidney | 1 | 2007 | 499 | 0.060 |
Why?
|
| Lipoproteins, LDL | 1 | 2003 | 77 | 0.060 |
Why?
|
| Cognition | 2 | 2018 | 527 | 0.060 |
Why?
|
| Heterozygote | 2 | 2014 | 54 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 535 | 0.060 |
Why?
|
| Apolipoproteins E | 2 | 2017 | 101 | 0.060 |
Why?
|
| Reference Values | 3 | 2008 | 230 | 0.060 |
Why?
|
| Exons | 2 | 2016 | 57 | 0.050 |
Why?
|
| Exercise Therapy | 2 | 2015 | 195 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 96 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2016 | 127 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2021 | 8 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 20 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2011 | 17 | 0.050 |
Why?
|
| Absorptiometry, Photon | 2 | 2015 | 130 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 101 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2020 | 23 | 0.050 |
Why?
|
| Age of Onset | 1 | 2020 | 98 | 0.050 |
Why?
|
| Diabetic Neuropathies | 2 | 2007 | 23 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 40 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2020 | 51 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2013 | 165 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2019 | 7 | 0.050 |
Why?
|
| Brazil | 1 | 2019 | 14 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2012 | 543 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 36 | 0.040 |
Why?
|
| Taiwan | 1 | 2018 | 8 | 0.040 |
Why?
|
| Australia | 1 | 2018 | 29 | 0.040 |
Why?
|
| Drosophila | 1 | 2019 | 37 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2019 | 62 | 0.040 |
Why?
|
| Homozygote | 2 | 2011 | 62 | 0.040 |
Why?
|
| Erythritol | 1 | 2018 | 1 | 0.040 |
Why?
|
| Trehalose | 1 | 2018 | 3 | 0.040 |
Why?
|
| Isoleucine | 1 | 2018 | 8 | 0.040 |
Why?
|
| Asparagine | 1 | 2018 | 6 | 0.040 |
Why?
|
| Mississippi | 1 | 2018 | 23 | 0.040 |
Why?
|
| Maryland | 1 | 2018 | 26 | 0.040 |
Why?
|
| Valine | 1 | 2018 | 27 | 0.040 |
Why?
|
| Leucine | 1 | 2018 | 30 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2018 | 53 | 0.040 |
Why?
|
| Linoleic Acid | 1 | 2017 | 14 | 0.040 |
Why?
|
| Arachidonic Acid | 1 | 2017 | 39 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 50 | 0.040 |
Why?
|
| ROC Curve | 2 | 2011 | 149 | 0.040 |
Why?
|
| Cholesterol | 1 | 2019 | 233 | 0.040 |
Why?
|
| Health Education | 1 | 2018 | 119 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2016 | 11 | 0.040 |
Why?
|
| Gait | 1 | 2017 | 87 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2016 | 24 | 0.040 |
Why?
|
| Public Health | 1 | 2017 | 68 | 0.040 |
Why?
|
| Walking | 1 | 2017 | 155 | 0.040 |
Why?
|
| Independent Living | 1 | 2017 | 58 | 0.040 |
Why?
|
| Fructosamine | 1 | 2016 | 5 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 5 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 18 | 0.040 |
Why?
|
| Introns | 1 | 2016 | 48 | 0.040 |
Why?
|
| Los Angeles | 2 | 2008 | 9 | 0.040 |
Why?
|
| Computational Biology | 1 | 2017 | 89 | 0.040 |
Why?
|
| Cystatin C | 1 | 2016 | 30 | 0.040 |
Why?
|
| Calcium | 2 | 2010 | 305 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2016 | 95 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2016 | 53 | 0.040 |
Why?
|
| Phosphates | 1 | 2015 | 26 | 0.040 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2015 | 13 | 0.040 |
Why?
|
| Iliac Artery | 1 | 2015 | 47 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 2 | 2006 | 97 | 0.040 |
Why?
|
| Troponin T | 1 | 2016 | 55 | 0.040 |
Why?
|
| Microvessels | 1 | 2015 | 27 | 0.040 |
Why?
|
| Factor XIII | 1 | 2015 | 3 | 0.040 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 5 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2015 | 40 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 6 | 0.030 |
Why?
|
| Carnitine | 1 | 2015 | 10 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 2 | 2007 | 51 | 0.030 |
Why?
|
| Databases, Nucleic Acid | 1 | 2014 | 8 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 32 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 7435 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 51 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 240 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 226 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2015 | 132 | 0.030 |
Why?
|
| Metabolic Equivalent | 1 | 2014 | 3 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 249 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2014 | 24 | 0.030 |
Why?
|
| Physical Exertion | 1 | 2014 | 13 | 0.030 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2013 | 3 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 63 | 0.030 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2013 | 1 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2013 | 8 | 0.030 |
Why?
|
| Lysophospholipase | 1 | 2013 | 5 | 0.030 |
Why?
|
| Genomics | 1 | 2014 | 87 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 12 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 2 | 2004 | 68 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 224 | 0.030 |
Why?
|
| Oceanic Ancestry Group | 1 | 2013 | 6 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2015 | 247 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 300 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2013 | 14 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 60 | 0.030 |
Why?
|
| Fatty Acid Desaturases | 1 | 2013 | 48 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 20 | 0.030 |
Why?
|
| Psychotherapy, Group | 1 | 2012 | 15 | 0.030 |
Why?
|
| Remission Induction | 1 | 2012 | 84 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 383 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2012 | 41 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2013 | 187 | 0.030 |
Why?
|
| Receptor, Melatonin, MT1 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 14 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2012 | 56 | 0.030 |
Why?
|
| Dietary Proteins | 1 | 2012 | 50 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 103 | 0.030 |
Why?
|
| Asia | 1 | 2011 | 16 | 0.030 |
Why?
|
| Africa | 1 | 2011 | 24 | 0.030 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2011 | 3 | 0.030 |
Why?
|
| Receptor, Melanocortin, Type 4 | 1 | 2011 | 4 | 0.030 |
Why?
|
| Social Support | 1 | 2012 | 150 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 17 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 21 | 0.030 |
Why?
|
| Systole | 1 | 2011 | 90 | 0.030 |
Why?
|
| Phosphorus | 1 | 2010 | 12 | 0.030 |
Why?
|
| Diastole | 1 | 2011 | 97 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 158 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 80 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 41 | 0.020 |
Why?
|
| Knee | 1 | 2010 | 31 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 192 | 0.020 |
Why?
|
| Government Regulation | 1 | 2010 | 36 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 251 | 0.020 |
Why?
|
| Program Development | 1 | 2010 | 82 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2010 | 68 | 0.020 |
Why?
|
| Aorta | 1 | 2010 | 113 | 0.020 |
Why?
|
| Skinfold Thickness | 1 | 2009 | 7 | 0.020 |
Why?
|
| Mortality | 1 | 2010 | 108 | 0.020 |
Why?
|
| Body Size | 1 | 2009 | 31 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 140 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 2397 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 84 | 0.020 |
Why?
|
| Gene Expression | 1 | 2010 | 347 | 0.020 |
Why?
|
| Urban Population | 1 | 2009 | 77 | 0.020 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2008 | 6 | 0.020 |
Why?
|
| Receptors, Calcitriol | 1 | 2008 | 11 | 0.020 |
Why?
|
| Ankle Joint | 1 | 2008 | 30 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2008 | 68 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2008 | 20 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2008 | 19 | 0.020 |
Why?
|
| Markov Chains | 1 | 2008 | 26 | 0.020 |
Why?
|
| Rural Population | 1 | 2009 | 229 | 0.020 |
Why?
|
| Observation | 1 | 2007 | 23 | 0.020 |
Why?
|
| Carotid Artery, Internal | 1 | 2007 | 29 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2006 | 15 | 0.020 |
Why?
|
| Estrogens | 1 | 2007 | 171 | 0.020 |
Why?
|
| Self Care | 1 | 2007 | 129 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2005 | 36 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 132 | 0.020 |
Why?
|
| Lipoproteins, VLDL | 1 | 2005 | 27 | 0.020 |
Why?
|
| Albumins | 1 | 2005 | 38 | 0.020 |
Why?
|
| Threonine | 1 | 2005 | 12 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2005 | 14 | 0.020 |
Why?
|
| Viscera | 1 | 2005 | 18 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 42 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2004 | 19 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2005 | 48 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2004 | 137 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2005 | 507 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 135 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2003 | 12 | 0.020 |
Why?
|
| Thrombophilia | 1 | 2003 | 8 | 0.020 |
Why?
|
| Cysteine | 1 | 2005 | 130 | 0.020 |
Why?
|
| World Health Organization | 1 | 2003 | 21 | 0.020 |
Why?
|
| Health Promotion | 1 | 2006 | 209 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2003 | 21 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 455 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 219 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2004 | 461 | 0.020 |
Why?
|
| Mexico | 1 | 2003 | 64 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 82 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 200 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 582 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1992 | 62 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 1992 | 69 | 0.010 |
Why?
|
| Education | 1 | 1989 | 30 | 0.010 |
Why?
|